Celldex Therapeutics, Inc. (CLDX) Free cash flow 2016–2025
Celldex Therapeutics, Inc. (CLDX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$213.7MFY2025 · since FY2016: -$115.8M → -$213.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$213.7M | -33.8% |
| FY2024 | -$159.7M | -46.4% |
| FY2023 | -$109.1M | -3.4% |
| FY2022 | -$105.6M | -69.8% |
| FY2021 | -$62.2M | -48.2% |
| FY2020 | -$42.0M | +11.0% |
| FY2019 | -$47.1M | +38.0% |
| FY2018 | -$76.0M | +25.2% |
| FY2017 | -$101.7M | +12.1% |
| FY2016 | -$115.8M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice